NEOTHETICS, INC. (NASDAQ:NEOT) Files An 8-K Other Events
Item8.01
| Other Events. |
On June26, 2017, Neothetics, Inc. (NASDAQ: NEOT) reported the
topline data for its Phase 2 proof-of-concept study of LIPO-202
for the reduction of submental subcutaneous fat.
The press release dated June26, 2017 announcing the updated
guidance of the timing of the release of topline data is attached
hereto as Exhibit 99.1.
Item9.01. |
Financial Statements and Exhibits |
(d)Exhibits.
ExhibitNo. |
Description | |
| 99.1 | Press Release, dated June 26, 2017. |
Neothetics, Inc. ExhibitEX-99.1 2 d370511dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 NEOTHETICS ANNOUNCES TOP-LINE RESULTS FOR PHASE 2 PROOF-OF-CONCEPT STUDY OF LIPO-202 FOR THE REDUCTION OF SUBMENTAL SUBCUTANEOUS FAT LIPO-202 did not show efficacy in the reduction of submental fat SAN DIEGO,…To view the full exhibit click here About NEOTHETICS, INC. (NASDAQ:NEOT)
Neothetics, Inc. is a clinical-stage specialty pharmaceutical company, which develops therapeutics. The Company focuses on localized fat reduction and body contouring. It focuses on the development of LIPO-202 for the reduction of central abdominal bulging due to subcutaneous fat in non-obese patients. It has completed Phase II development of LIPO-202. LIPO-202 is administered in a subcutaneous injection procedure that activates a natural metabolic process to shrink fat cells, without killing them, resulting in localized fat reduction, measurable results within four weeks and minimal risk with no downtime. The Company is developing a product candidate, LIPO-102, an injectable form of a combination of salmeterol xinafoate and fluticasone propionate. LIPO-102 is indicated for the treatment of the orphan indication of symptomatic exophthalmos, or protrusion of the eye from the orbit, associated with thyroid-related eye disease caused by the expansion of fat and muscle behind the eye.